Through PRECOG (79), we found that high ST6GALNAC4 expression, among all sialyltransferases, is the strongest predictor of adverse patient outcomes in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), and Burkitt lymphoma (BL), which notably all have high MYC activity (Fig. 4I) (80). Here, MYC is linked to diffuse large B-cell lymphoma.